for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mabion SA

MABP.WA

Latest Trade

97.80PLN

Change

4.00(+4.26%)

Volume

5,214

Today's Range

93.90

 - 

98.00

52 Week Range

66.00

 - 

99.90

As of on the Warsaw Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
93.80
Open
93.90
Volume
5,214
3M AVG Volume
0.13
Today's High
98.00
Today's Low
93.90
52 Week High
99.90
52 Week Low
66.00
Shares Out (MIL)
13.72
Market Cap (MIL)
1,315.82
Forward P/E
-20.36
Dividend (Yield %)
--

Next Event

Mabion SA Annual Shareholders Meeting

Latest Developments

More

Mabion Q3 Net Loss Widens To 16.7 Mln Zlotys

Mabion Q2 Net Loss Shrinks To 16.7 Mln Zlotys

Mabion Plant In Konstantynow Lodzki Gets Second GMP Certificate

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mabion SA

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Industry

Biotechnology & Drugs

Contact Info

ul. gen. Mariana Langiewicza 60

+48.42.2077890

https://www.mabion.eu/

Executive Leadership

Maciej Wieczorek

Chairman of the Supervisory Board

Jozef Banach

Independent Vice Chairman of the Supervisory Board

Jolanta Baranowska

Chief Accounting Officer

Grzegorz Grabowicz

Member of the Management Board

Slawomir Jaros

Member of the Management Board

Key Stats

2.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, PLN)

2016

0.0K

2017

0.0K

2019(E)

0.0K
EPS (PLN)

2016

-4.780

2017

-4.910

2019(E)

-4.710
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-99.95
Return on Equity (TTM)
-49.66

Latest News

Latest News

BRIEF-Mabion Q2 Net Loss Shrinks To 16.7 Mln Zlotys

* REPORTED ON THURSDAY Q2 NET LOSS OF 16.7 MILLION ZLOTYS VERSUS LOSS OF 26.8 MILLION ZLOTYS YEAR AGO

BRIEF-Mabion Q1 Net Loss Widens To 15.0 Mln Zlotys

* REPORTED ON THURSDAY Q1 NET LOSS OF 15.0 MILLION ZLOTYS VERSUS LOSS OF 14.3 MILLION ZLOTYS YEAR AGO

BRIEF- Mabion Q3 Net Loss Narrows To 11.1 Mln Zlotys

* SAID ON THURSDAY Q3 NET LOSS WAS AT 11.1 MLN ZLOTYS VS LOSS OF 13.2 MLN ZLOTYS YR AGO

BRIEF-Mabion Files Second Patent Application

* SAID ON FRIDAY IT FILED A SECOND PATENT APPLICATION FOR ITS INVENTION FROM AREA OF APPLICATION OF MABIONCD20 IN TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS 'LOW AGGREGATE ANTI CD20 LIGAND FORMULATION'

BRIEF-Mabion Q2 Net Loss Widens To 26.8 Mln Zlotys

* REPORTED ON THURSDAY Q2 NET LOSS OF 26.8 MLN ZLOTYS VS LOSS 12.5 MLN ZLOTYS YEAR AGO

BRIEF-EBRD Buys 5.72% Stake Of Mabion

* EUROPEAN BANK FOR RECONSTRUCTION AND DEVELOPMENT (EBRD) BUYS ABOUT 5.72% STAKE IN CO IN SHARES ACQUISITION TRANSACTION

BRIEF-EBRD, PFR Life Science Among Investors Of Mabion

* AMONG INVESTORS WHO ARE TO INVEST IN CO ARE EUROPEAN BANK FOR RECONSTRUCTION AND DEVELOPMENT (EBRD) AND PFR LIFE SCIENCE SP. Z O.O.

BRIEF-Mabion Confirms Final Results Of Clinical Trial Of MabionCD20 RZS

* CONFIRMS THAT POSITIVE PRELIMINARY RESULTS OF CLINICAL TRIAL OF MABIONCD20 RZS CHANGE ITS STATUS TO FINAL

BRIEF-Mabion Obtains 174.8 Mln Zloty Financing Through Loan From Shareholder

* OBTAINS 174.8 MILLION ZLOTY FINANCING THROUGH LOAN FROM SHAREHOLDER

BRIEF-Mabion Files For Patent For Its Therapy Of Multiple Sclerosis

* FILES FOR PATENT FOR ITS INVENTION 'COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND' Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mabion Q3 Net Loss Narrows To 13.2 Million Zlotys

* SAID ON WEDNESDAY THAT ITS Q3 NET LOSS WAS 13.2 MILLION ZLOTYS VERSUS LOSS OF 14.4 MILLION ZLOTYS

BRIEF-Mabion to get 28 mln zloty subsidy for biotech medicine development

* SAID ON WEDNESDAY THAT NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT IN POLAND HAS SIGNED THE CONTRACT TO FINANCE THE COMPANY'S PROJECT FOR DEVELOPMENT OF A BIOTECH MEDICINE

BRIEF-Funds represented by Amathus TFI lower their stake in Mabion to 0.82 pct

* FUNDS REPRESENTED BY AMATHUS TFI SA LOWER THEIR STAKE IN CO TO 0.82 PERCENT FROM 6.86 PCT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mabion gets around 27 mln zloty subsidy for its project

* GETS AROUND 27 MILLION ZLOTY SUBSIDY FOR WORLDWIDE IMPLEMENTATION OF ITS BIOTECH DRUG MABION CD20 FROM NCBIR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mabion Q2 net loss narrows to 12.5 mln zlotys

* SAID ON FRIDAY THAT Q2 OPERATING LOSS WAS 14.6 MILLION ZLOTYS VERSUS LOSS OF 13.6 MILLION ZLOTYS YEAR AGO

BRIEF-Mabion: positive prelim results of clinical trial of MabionCD20 RZS in baseline ACR 20 endpoint

* SAYS POSITIVE PRELIMINARY RESULTS OF CLINICAL TRIAL OF MABIONCD20 RZS IN BASELINE ACR 20 ENDPOINT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mabion Q1 net loss widens to 12.9 mln zlotys

* REPORTED ON MONDAY Q1 OPERATING LOSS AT 14.4 MILLION ZLOTYS VERSUS LOSS OF 10.1 MILLION ZLOTYS A YEAR AGO

BRIEF-Mabion Q1 prelim. net loss at 16 mln zlotys

* SAID ON WEDNESDAY THAT ITS Q1 PRELIM. NET LOSS WAS AT 16 MILLION ZLOTYS ON REVENUE OF 0 ZLOTYS

BRIEF-Mabion FY 2016 net loss widens to 55.8 mln zlotys

* Informed on Tuesday that its FY 2016 revenue was 0 zlotys versus 2.7 million zlotys ($697,566) a year ago

BRIEF-Mabion FY 2016 net loss increases by 44.2 mln zlotys following changes in accounting policy

* The company's FY 2016 net loss increases by 44.2 million zlotys ($11.33 million) following changes in accounting policy Source text for Eikon: Further company coverage: ($1 = 3.9025 zlotys) (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up